Skip to Content
Merck
  • Mutation in ST6GALNAC5 identified in family with coronary artery disease.

Mutation in ST6GALNAC5 identified in family with coronary artery disease.

Scientific reports (2014-01-09)
Kolsoum InanlooRahatloo, Amir Farhang Zand Parsa, Klaus Huse, Paniz Rasooli, Saeid Davaran, Matthias Platzer, Marcel Kramer, Jian-Bing Fan, Casey Turk, Sasan Amini, Frank Steemers, Kevin Gunderson, Mostafa Ronaghi, Elahe Elahi
ABSTRACT

We aimed to identify the genetic cause of coronary artery disease (CAD) in an Iranian pedigree. Genetic linkage analysis identified three loci with an LOD score of 2.2. Twelve sequence variations identified by exome sequencing were tested for segregation with disease. A p.Val99Met causing mutation in ST6GALNAC5 was considered the likely cause of CAD. ST6GALNAC5 encodes sialyltransferase 7e. The variation affects a highly conserved amino acid, was absent in 800 controls, and was predicted to damage protein function. ST6GALNAC5 is positioned within loci previously linked to CAD-associated parameters. While hypercholesterolemia was a prominent feature in the family, clinical and genetic data suggest that this condition is not caused by the mutation in ST6GALNAC5. Sequencing of ST6GALNAC5 in 160 Iranian patients revealed a candidate causative stop-loss mutation in two other patients. The p.Val99Met and stop-loss mutations both caused increased sialyltransferase activity. Sequence data from combined Iranian and US controls and CAD affected individuals provided evidence consistent with potential role of ST6GALNAC5 in CAD. We conclude that ST6GALNAC5 mutations can cause CAD. There is substantial literature suggesting a relation between sialyltransferase and sialic acid levels and coronary disease. Our findings provide strong evidence for the existence of this relation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human ST6GALNAC5